In vivo, tumor load reduction and higher CD8+T cells infiltration in tumor were observed in tumor-bearing mice treated by dasatinib (a tyrosine kinase inhibitor of DDR2) plus anti-PD-1 (Tu et al., 2019). This evidence concerns the gene CD8A and neoplasm.